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Purpose: The treatment of osteoarthritis (OA) is limited by sparse
knowledge of the pathogenesis, which can be partly related to lack
of investigative methods to obtain continuous recordings in joint
and joint-near tissue. Microdialysis is a minimally invasive method
which allows for continuous determination of substances locally
and in vivo. In this study we have examined levels of 2 biomarkers
of cartilage, Cartilage Oligomeric Matrix Protein (COMP) and
Aggrecan, measured by microdialysis in 2 different regions of the
knee.
Methods: Subjects with conﬁrmed OA were regionally anaesthe-
sized and 2 microdialysis catheters containing a 3 cm region with
pores allowing for molecules of a size up to 3000 kDa to pass
the membrane, were positioned under ultrasonographic guidance.
One was placed intraarticularly in the suprapatellar pouch and
another one outside the joint but synovium-close in the medial
parapatellar region. The microdialysis catheters were perfused at
a slow rate with Ringer-acetate solution and radioactively labelled
glucose allowing for determination of relative recovery (RR) of
the catheters. Samples were collected continuously for a period
ranging from 100 - 180 min for each subject.
Results: Mean RR, an indicator of membrane functionality, was
56±12% for the intraarticular catheters and 52±15% for the
synovium-close catheters.
Aggrecan and COMP levels in the dialysate were measured by
ELISA and later corrected for RR. Synovium-close and intraartic-
ular levels of Aggrecan ranged from 21.70 to 92.95 ng/ml (n = 13)
and 53.25 to 731.80 ng/ml (n = 8) respectively (Fig. 1), and simi-
larly we found levels of COMP to range from 6.69 to 47.12 U/l (n =
8) intraarticularly and 2.70 to 18.14 U/l (n = 9) synovium-close (Fig.
2). Both Aggrecan and COMP concentrations were signiﬁcantly
higher intraarticularly than in the synovium-near extraarticular tis-
sue. Serum levels of both markers were also determined and were
in the range of previous studies on OA patients.
Figure 1. Levels of Aggrecan measured intraarticularly (I.A) and synovium-close
(Syn) by microdialysis. Values corrected for relative recovery (p<0.05 on log-
transformed data).
Conclusions: Microdialysis of the knee with OA has never been
done before. This study demonstrates that it is possible to perform
this and to obtain relative recoveries comparable to those of other
studies where microdialysis has been used in other types of
Figure 2. Levels of Cartilage Oligomeric Matrix Protein (COMP) measured in-
traarticularly (I.A.) and synovium-close (Syn) by microdialysis. Values corrected
for relative recovery (p<0.05 on log-transformed data).
tissue. Levels of Aggrecan and COMP have for the ﬁrst time been
measured continuously, both within the joint and peri-synovial, and
it was found that peri-synovial concentrations were not as high as
the intraarticular ones.
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Purpose: Our group recently published a cross-sectional study
of the utility of transforming growth factor-beta 1 (TGF-β1) as
a biomarker of OA, showing no signiﬁcant association between
serum TGF-β1 levels and the presence or severity of radiographic
OA (rOA) at the knee or hip [1]. The current longitudinal analysis
was designed to test the utility of serum TGF-β1, as a predictor
of incident and progressive rOA at the knee in African Americans
(AAs) and Caucasians.
Methods: Baseline serum TGF-β1 levels were available for 330
participants in the Johnston County Osteoarthritis Project. Serum
TGF-β1 was measured using a sandwich ELISA kit from Biosource
International (Camarillo, CA); manufacturer reported precision was
5.5-6.2% intra-assay and 6.6-7.9% inter-assay. Paired longitudinal
knee ﬁlms were available for 329 individuals (658 knees). Incident
knee rOA was deﬁned in two ways: 1) development of K-L grade
≥2 in a knee with K-L grade <2 at baseline, and 2) development of
K-L grade ≥1 in a knee with K-L grade=0 at baseline. Progression
of knee rOA was also deﬁned in two ways: 1) an increase by ≥1 K-
L grade in a knee that was a K-L grade ≥2 at baseline, and 2) an in-
crease by ≥1 K-L grade in a knee that was a K-L grade ≥1 at base-
line. Incident osteophytes and joint space narrowing (JSN) were
identiﬁed in knees with an OST or JSN grade of 0 at baseline and
≥1 at follow-up; progression in OST and JSN was deﬁned as an in-
crease of ≥ 1 grade in a knee with at least grade 1 at baseline. The
natural logarithm transformation was used to produce near-normal
distributions for serum TGF-β1 (ln TGF-β1), which was used as a
continuous variable in analyses. Multivariable time-to-event regres-
sion models using the Weibull distribution were used to provide
hazard ratios for each one-unit increase in the level of serum
lnTGF-β1 with rOA outcomes, accounting for variable follow up
times (interval censoring) and clustering of 2 knees per individual.
Interaction terms were considered signiﬁcant at the p <0.01 level.
Results: The mean (±SD) age of the sample was 62±10 years,
and the mean BMI was 30±7 kg/m2; 61% were women and 42%
were AA. The mean (± SD) serum TGF-β1 was 17.8±6.1 ng/ml
(range 6.1-40.9 ng/ml), and the mean (± SD) follow up time was
